Cheng‐Yu Chang

527 total citations
29 papers, 388 citations indexed

About

Cheng‐Yu Chang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Cheng‐Yu Chang has authored 29 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 7 papers in Surgery. Recurrent topics in Cheng‐Yu Chang's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Cheng‐Yu Chang is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Cheng‐Yu Chang collaborates with scholars based in Taiwan, United States and Australia. Cheng‐Yu Chang's co-authors include Shih‐Chieh Chang, Yi-Chun Lai, Kuan‐Chih Chow, Wing‐Kai Chan, Chen‐Hsin Chen, Chong‐Jen Yu, Chung‐Yu Chen, Chiung‐Yu Chen, Yu‐Feng Wei and Shen–Kou Tsai and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Medicine.

In The Last Decade

Cheng‐Yu Chang

28 papers receiving 373 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cheng‐Yu Chang Taiwan 11 251 171 85 77 66 29 388
Paloma Leticia Martín-Moreno Spain 11 90 0.4× 99 0.6× 44 0.5× 105 1.4× 67 1.0× 37 386
Hiroko Tsukada Japan 12 257 1.0× 130 0.8× 33 0.4× 118 1.5× 49 0.7× 44 474
Benjamin Ng Australia 8 401 1.6× 75 0.4× 16 0.2× 169 2.2× 101 1.5× 14 592
Cosimo Lequaglie Italy 13 285 1.1× 162 0.9× 12 0.1× 151 2.0× 67 1.0× 43 480
A Goldman United Kingdom 7 169 0.7× 80 0.5× 51 0.6× 100 1.3× 68 1.0× 9 300
Takahisa Matsuoka Japan 10 325 1.3× 54 0.3× 20 0.2× 93 1.2× 23 0.3× 45 393
Takehiro Otoshi Japan 11 332 1.3× 213 1.2× 10 0.1× 62 0.8× 44 0.7× 30 489
Lina Zuccatosta Italy 14 383 1.5× 62 0.4× 21 0.2× 116 1.5× 14 0.2× 51 495
Kyungjong Lee South Korea 14 286 1.1× 77 0.5× 10 0.1× 73 0.9× 43 0.7× 47 416
K.F. Siu China 13 404 1.6× 82 0.5× 42 0.5× 530 6.9× 66 1.0× 19 631

Countries citing papers authored by Cheng‐Yu Chang

Since Specialization
Citations

This map shows the geographic impact of Cheng‐Yu Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng‐Yu Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng‐Yu Chang more than expected).

Fields of papers citing papers by Cheng‐Yu Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheng‐Yu Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng‐Yu Chang. The network helps show where Cheng‐Yu Chang may publish in the future.

Co-authorship network of co-authors of Cheng‐Yu Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Cheng‐Yu Chang. A scholar is included among the top collaborators of Cheng‐Yu Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheng‐Yu Chang. Cheng‐Yu Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chang, Cheng‐Yu. (2024). Exploring the evolution of T cell function and diversity across different stages of non-small cell lung cancer. American Journal of Cancer Research. 14(3). 1243–1257.
3.
Kuo, Yao-Wen, Chung‐Yu Chen, Sumei Wang, et al.. (2024). Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy. The Oncologist. 29(4). e498–e506. 7 indexed citations
4.
5.
Cheng, Shih-Lung, et al.. (2023). The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19. Drug Design Development and Therapy. Volume 17. 87–92. 1 indexed citations
6.
7.
Chang, Cheng‐Yu, Chung‐Yu Chen, Shih‐Chieh Chang, et al.. (2023). Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment. Frontiers in Oncology. 13. 1104098–1104098. 1 indexed citations
8.
Chang, Cheng‐Yu, Yu-Feng Wei, Chung‐Yu Chen, et al.. (2023). Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan. Frontiers in Medicine. 10. 1242260–1242260. 4 indexed citations
9.
Chang, Cheng‐Yu, Chung‐Yu Chen, Shih‐Chieh Chang, Yi-Chun Lai, & Yu‐Feng Wei. (2021). Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer. Cancer Management and Research. Volume 13. 7187–7201. 11 indexed citations
10.
Chen, You‐Yi, Shih‐Chieh Chang, Cheng‐Yu Chang, et al.. (2021). Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients. BMC Cancer. 21(1). 1225–1225. 1 indexed citations
11.
Tseng, Jeng‐Sen, Chih‐Liang Wang, Ming‐Shyan Huang, et al.. (2014). Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma. PLoS ONE. 9(9). e107160–e107160. 11 indexed citations
12.
13.
Chang, Cheng‐Yu, et al.. (2013). Risk factors in patients with AFB smear-positive sputum who receive inappropriate antituberculous treatment. Drug Design Development and Therapy. 7. 53–53. 9 indexed citations
14.
Chang, Shih‐Chieh, Cheng‐Yu Chang, Yi-Chun Lai, et al.. (2012). Gefitinib-Related Interstitial Lung Disease in Taiwanese Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 14(1). 55–61. 12 indexed citations
15.
Chang, Cheng‐Yu, et al.. (2012). The value of positron emission tomography in early detection of lung cancer in high‐risk population: a systematic review. The Clinical Respiratory Journal. 7(1). 1–6. 5 indexed citations
16.
Chang, Cheng‐Yu, et al.. (2011). Adenoid Cystic Carcinoma of Trachea Treated with Tumor Curettage and Adjuvant Intensity Modulated Radiation Therapy. Southern Medical Journal. 104(1). 68–70. 9 indexed citations
17.
Chang, Cheng‐Yu, Shih-Lung Cheng, & Shih‐Chieh Chang. (2011). Conservative Treatment of Severe Tracheal Laceration After Endotracheal Intubation. Respiratory Care. 56(6). 861–862. 12 indexed citations
18.
Chang, Shih‐Chieh, Cheng‐Yu Chang, Chiung‐Yu Chen, & Chong‐Jen Yu. (2010). Successful Erlotinib Rechallenge after Gefitinib-Induced Acute Interstitial Pneumonia. Journal of Thoracic Oncology. 5(7). 1105–1106. 29 indexed citations
19.
Tsai, Shen–Kou, et al.. (2010). Emergent bedside real-time three-dimensional transesophageal echocardiography in a patient with cardiac arrest following a caesarean section. European Journal of Echocardiography. 12(3). E16–E16. 15 indexed citations
20.
Chang, Cheng‐Yu, et al.. (2008). Measurement of Human Erythrocyte C4d to Erythrocyte Complement Receptor 1 Ratio in Cardiac Transplant Recipients With Acute Symptomatic Allograft Failure. Transplantation Proceedings. 40(8). 2638–2642. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paloma Leticia Martín-Moreno Breakdown of academic impact, for papers by Hiroko Tsukada Breakdown of academic impact, for papers by Benjamin Ng Breakdown of academic impact, for papers by Cosimo Lequaglie Breakdown of academic impact, for papers by A Goldman Breakdown of academic impact, for papers by Takahisa Matsuoka Breakdown of academic impact, for papers by Takehiro Otoshi Breakdown of academic impact, for papers by Lina Zuccatosta Breakdown of academic impact, for papers by Kyungjong Lee Breakdown of academic impact, for papers by K.F. Siu
Rankless by CCL
2026